B · Normal
[Hengrui Medicine: More than 40 marketing applications are expected to be approved in the next two years] Hengrui Medicine said at the 2026 semi-annual performance briefing on September 10 that more than 40 marketing applications are expected to be approved during 2027-2028, covering 5 major treatment areas. Among them, potential blockbuster products include the first domestic single-target HER3 ADC drug SHR-A2009 to be applied for marketing.
medicine 🕐 2026-09-10 14:33
#A20 #medicine
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Jiangsu: From January to August, the added value of industries above designated 09-22 11:22 [Novo Nordisk: Create a new business segment called blood and endocrine diseases 09-21 16:23 September 21st, Novo Nordisk stated that it plans to expand its production capac 09-21 16:06 September 21st, Novo Nordisk aims to have sales of product lines under developme 09-21 16:06 [Pharmaceutical sector’s rally expands Huaren Pharmaceutical and more than a doz 09-21 10:43 On September 18th, Anthropic established a biological laboratory for artificial 09-18 18:19

Comments

0/500
Captcha (click to refresh)
No comments yet